PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis

被引:48
作者
Travaglino, Antonio [1 ]
Raffone, Antonio [2 ]
Saccone, Gabriele [2 ]
Insabato, Luigi [1 ]
Mollo, Antonio [2 ]
De Placido, Giuseppe [2 ]
Zullo, Fulvio [2 ]
机构
[1] Univ Naples Federico II, Sch Med, Dept Adv Biomed Sci, Anat Pathol Unit, Naples, Italy
[2] Univ Naples Federico II, Sch Med, Dept Neurosci Reprod Sci & Dent, Gynecol & Obstet Unit, Via Sergio Pansini 5, I-80131 Naples, Italy
关键词
Immunohistochemistry; Fertility-sparing; LNG-IUD; Endometrial intraepithelial neoplasia; Progestin; Progesterone resistance; Phosphatase and tensin homolog; COMPLEX ATYPICAL HYPERPLASIA; THERAPY RESPONSE; YOUNG-WOMEN; PROGESTIN; EXPRESSION; CARCINOMA; ADENOCARCINOMA; ESTROGEN; CONTEXT; RISK;
D O I
10.1016/j.ejogrb.2018.10.025
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: Several markers have been studied to predict the responsiveness of endometrial hyperplasia (EH) and early endometrial cancer (EEC) to progestin therapy. PTEN has played a major role in this field, although its predictive significance is still undefined. We aimed to assess if loss of PTEN expression on pre-treatment endometrial specimen may be a predictive markers of response to progestins in EH and EEC. Study Design: MEDLINE, EMBASE, Web of Sciences, Scopus, ClinicalTrial.gov, OVID and Cochrane Library were searched for relevant articles from the inception to May 2018. All studies assessing PTEN expression as predictive marker in EH and EEC treated with progestin were included. Relative risk (RR) for therapy failure was calculated with 95% confidence interval (CI) and a significant p-value<0.05, with a subgroup analysis based on the histologic category (EEC or EH) and the administration route of progestin (oral or intrauterine). Results: Seven cohort studies assessing 376 patients were included. PTEN loss was not significantly associated with the outcome of therapy in the overall analysis (RR = 1.24, 95% CI, 0.88-1.76, p = 0.21), in + the subgroups of EEC (RR = 0.89, 0.32-2.49, p = 0.83), EH (RR = 1.30, 0.90-1.87 p = 0.16), oral progestin (RR = 1.25 0.88-1.79, p = 0.22) and intrauterine device (RR = 1.02, 0.36-2.87, p = 0.97). Conclusion: PTEN seems not to be useful as predictive marker of response to the conservative treatment of EH and EC, regardless of the administration route (oral or intrauterine) of progestins. We advise future researcher not to further assess PTEN as a stand-alone predictive marker. (C) 2018 Elsevier B.V. All rights reserved.
引用
收藏
页码:104 / 110
页数:7
相关论文
共 50 条
  • [41] Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis
    Matanes, Emad
    Volodarsky-Perel, Alexander
    Eisenberg, Neta
    Rottenstreich, Misgav
    Yasmeen, Amber
    Mitric, Cristina
    Lau, Susie
    Salvador, Shannon
    Gotlieb, Walter H.
    Kogan, Liron
    JOURNAL OF MINIMALLY INVASIVE GYNECOLOGY, 2021, 28 (05) : 947 - 956
  • [42] Efficacy of drugs treatment in patients with endometrial hyperplasia with or without atypia: A systematic review and network meta-analysis
    Yao, Yingsha
    Xu, Shuhang
    Wang, Ting
    Jiang, Ruoan
    MEDICINE, 2024, 103 (38) : e39619
  • [43] Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis
    Herrera Cappelletti, Erica
    Humann, Jonas
    Torrejon, Rafael
    Gambadauro, Pietro
    HUMAN REPRODUCTION UPDATE, 2022, 28 (02) : 282 - 295
  • [44] Diagnostic accuracy of endometrial sampling tests for detecting endometrial cancer: a systematic review and meta-analysis
    Sakna, Noha Abdelsattar
    Elgendi, Marwa
    Salama, Mohamed Hamed
    Zeinhom, Ahmed
    Labib, Somia
    Nabhan, Ashraf Fawzy
    BMJ OPEN, 2023, 13 (06):
  • [45] Current research of Assisted Reproductive Technology for women with early endometrial cancer and atypical endometrial hyperplasia after conservative treatment
    Jiang, Yan-le
    Lin, Yan-ying
    Chen, Chen-xi
    Li, Yu-xin
    Xie, Huang-yan
    Zheng, Bei-hong
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [46] Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response?
    Dore, Molly
    Filoche, Sara
    Danielson, Kirsty
    Henry, Claire
    GYNECOLOGIC ONCOLOGY REPORTS, 2021, 36
  • [47] Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study
    Raffone, Antonio
    Catena, Ursula
    Travaglino, Antonio
    Masciullo, Valeria
    Spadola, Saveria
    Della Corte, Luigi
    Piermattei, Alessia
    Insabato, Luigi
    Zannoni, Gian Franco
    Scambia, Giovanni
    Zullo, Fulvio
    Bifulco, Giuseppe
    Fanfani, Francesco
    Sardo, Attilio Di Spiezio
    GYNECOLOGIC ONCOLOGY, 2021, 161 (03) : 795 - 801
  • [48] The Oncogenic Potential of Endometrial Polyps A Systematic Review and Meta-Analysis
    Lee, Stephanie Cruz
    Kaunitz, Andrew M.
    Sanchez-Ramos, Luis
    Rhatigan, Ronald M.
    OBSTETRICS AND GYNECOLOGY, 2010, 116 (05) : 1197 - 1205
  • [49] Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis
    Gallos, Ioannis D.
    Yap, Jason
    Rajkhowa, Madhurima
    Luesley, David M.
    Coomarasamy, Arri
    Gupta, Janesh K.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 207 (04) : 266.e1 - 266.e12
  • [50] Prevalence of Human Papillomavirus in endometrial cancer: A systematic review and meta-analysis
    Olesen, Tina Bech
    Svahn, Malene Frosig
    Faber, Mette Tuxen
    Duun-Henriksen, Anne Katrine
    Junge, Jette
    Norrild, Bodil
    Kjaer, Susanne K.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (01) : 206 - 215